<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03638661</url>
  </required_header>
  <id_info>
    <org_study_id>YS</org_study_id>
    <nct_id>NCT03638661</nct_id>
  </id_info>
  <brief_title>n-3 Fatty Acids in Enteral Formula on NK Cell Activity</brief_title>
  <acronym>YS</acronym>
  <official_title>Effect of Immune-enhancing Enteral Nutrition Formula Enriched With Vegetable Derived n-3 Fatty Acids on NK Cell Activity in Hospitalized Patients for Rehabilitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study was to investigate the NK cell activity alternations and related
      cytokine changes in comparison with soybean oil used formula (control) and the canola and
      flaxseed oil used n-3 fatty acid enriched formula (n3EN, test) with non-surgical hospitalized
      patients for rehabilitation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were randomized to receive one of two types of enteral nutrition formula: soybean
      oil used enteral nutrition (control), vegetable (canola, flaxseed) derived n-3 fatty acid
      enriched enteral nutrition (n3EN). Blood samples were collected on the first day and 14 days
      after consumption of each formula and anthropometric parameters were collected. Hematology
      and biochemical values were analyzed and NK cell activities and serum cytokine productions
      were measured.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 11, 2015</start_date>
  <completion_date type="Actual">July 30, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The ready-to-use soybean used formula and n3EN formula had identical packaging with no differences in appearance, texture, or smell.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>NK cell activity</measure>
    <time_frame>Baseline</time_frame>
    <description>NK cell activity (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cytokine values</measure>
    <time_frame>Baseline</time_frame>
    <description>(IL-12, IFN-γ, IL-1β , IL-6 and TNF-α)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Enteral Nutrition</condition>
  <arm_group>
    <arm_group_label>n-3 fatty acid enriched formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those assigned to the n3EN group received vegetable n-3 fatty acid enriched formula by tube feeding (product; Yonsei Dairy Co., Seoul, South Korea).
vegetable (canola, flaxseed) derived n-3 fatty acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>soybean oil used formula</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients assigned to the control group received a soybean used formula by tube feeding.
soybean used formula</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vegetable (canola, flaxseed) derived n-3 fatty acid</intervention_name>
    <description>vegetable (canola, flaxseed) derived n-3 fatty acid was used for fat source.</description>
    <arm_group_label>n-3 fatty acid enriched formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>soybean oil</intervention_name>
    <description>soybean oil used formula</description>
    <arm_group_label>soybean oil used formula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who were admitted to the Severance Hospital Rehabilitation Department ,
             enteral tube feeding patient, Adult male and female patients aged 19 years and over,
             Patients who signed the consent form

        Exclusion Criteria:

          -  Patient with nausea

          -  Patients with hepatic impairment (total bilirubin concentration&gt; 3.5 mg / dl)

          -  Patients with renal impairment (serum creatinine concentration&gt; 3 mg / dl or requiring
             peritoneal or hemodialysis) diabetic patients

          -  Patients who are undergoing chemotherapy or who are within 1 month of the end of
             chemotherapy

          -  Patients whose life expectancy is less than 1 month

          -  Pregnant women and women who are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <last_update_submitted>August 16, 2018</last_update_submitted>
  <last_update_submitted_qc>August 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Jong Ho Lee</investigator_full_name>
    <investigator_title>Professor, Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03638661/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

